Значение особенностей действия антиагрегантов для выбора терапии сосудистого больного

УДК 616.155.2:615.035

  • Людмила Ивановна Бурячковская ФГБУ «НМИЦ кардиологии» МЗ РФ
  • Н. В. Ломакин ФГБУ «ЦКБП» УД Президента РФ
  • А. Б. Сумароков ФГБУ «НМИЦ кардиологии» МЗ РФ
  • Ю. В. Доценко ФГБУ «НМИЦ кардиологии» МЗ РФ

Аннотация

Резюме. В обзорной статье представлены современные данные о клинико-фармакологических особенностях трех современных антиагрегантных препаратов — клопидогрела (плавикс и его генерики), тикагрелора (брилинта) и прасугрела (эффиент). Рассмотрены особенности каждого из препаратов и показания к их назначению в различных клинических ситуациях.

Биографии авторов

Бурячковская Людмила Ивановна — д.м.н., ведущий научный сотрудник ФГБУ «НМИЦ кардиологии» МЗ РФ. Адрес: ул. Черепковская, 15а, Москва, Россия, 121552.

E-mail: livbur@mail.ru.

ЛомакинН. В. — к.м.н., руководитель отделения кардиореанимации ФГБУ «ЦКБП» УД Президента РФ. Адрес: ул. Маршала Тимошенко, 15, Москва, Россия, 121359.

СумароковА. Б. — к.м.н., старший научный сотрудник ФГБУ «НМИЦ кардиологии» МЗ РФ. Адрес: ул. Черепковская, 15а, Москва, Россия, 121552.

Доценко Ю. В. — к.м.н., младший научный сотрудник ФГБУ «НМИЦ кардиологии» МЗ РФ. Адрес: ул. Черепковская, 15а, Москва, Россия, 121552.

Литература

  1. Patrono C., Andreotti F., Arnesen H. et al. Antiplatelet agents for
    the treatment and prevention of atherothrombosis. Eur Heart J.
    2011; 32 (23): 2922–32.

  2. Koln P., Windecker S., Alfonso F. et al. 2014 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2014; 35: 2541–
    619.

  3. Montalescott J., Collet J. P., Ecollan P. et al. Effect of prasugrel pretreatment strategy in patients undergoing percutaneous coronary
    intervention for NSTEMI. The ACCOAST-PCI Study. JACC. 2014;
    64 (24): 2563–71.

  4. Amsterdam E., Wenger N., Brindis R. et al. 2014 AHA/ACC Guideline for the management of patients with Non-ST-Elevation Acute
    Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 64 (24): e139-e228.

  5. Gurbel P., Bliden K., Butler K. et al. Randomized double-blind
    assessment of the ONSET and OFFSET of the antiplatelet effects
    of ticagrelor versus clopidogrel in patients with stable coronary
    artery disease. The ONSET/OFFSET Study. Circulation. 2009; 120:
    2577–85.

  6. Puymirat E., Schiele F., Zeller M. et al. Do randomized clinical
    trial selection criteria reflect levels of risk as observed in a general population of acute myocardial infarction survivors? The PEGASUS trial in the light of the FAST-MI 2005 registry. Intern J Cardiol. 2016; 223: 604–10.

  7. Wisman P., Roest M., Asselbergs F. et al. Platelet‐reactivity tests
    identify patients at risk of secondary cardiovascular events: a systematic review and meta‐analysis. J Thromb Haemost. 2014; 12
    (5): 736–47.

  8. Dalal J., Digrajkar A., Gandhi A.Oral antiplatelet therapy and platelet inhibition: An experience from a tertiary care center. Indian
    Heart J. 2016; 68 (5): 624–31.

  9. Bonello L., Pansieri M., Mancini J. et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events
    after percutaneous coronary intervention in acute coronary syndromes. JACC. 2011; 58: 467–73.

  10. Mehta S., Tanguay J-F., Eikelboom J. et al. CURRENT-OASIS7
    trial investigators. High dose versus standard-dose clopidogrel
    and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS7): a randomised factorial trial. Lancet. 2010; 376 (9748): 1233–43.

  11. Aradi D., Tornyos A., Pinter T. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. JACC. 2014; 63 (11): 1061–70.

  12. Tantry U., Bonello L., Aradi D. For the Working Group on OnTreatment Platelet Reactivity. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. JACC. 2013; 62 (24):
    2261–73.

  13. StuckeyT. D., KirtaneA. J., BrodieB. R. et al. Impact of aspirin and
    clopidogrel hyporesponsiveness in patients treated with drug-eluting stents: 2-year results of a prospective, multicenter registry study.
    JACC Cardiovasc Interv. 2017; 10 (16) [Epub ahead of print]. DOI:
    10.1016/j.jcin.2017.05.059.

  14. Becker R., Bassand J., Budai A. et al. Bleeding complications with
    the P2Y12 receptor antagonists clopidogrel and ticagrelor in the
    PLATelet inhibition and patient Outcomes (PLATO) Trial. Eur
    Heart J. 2011: 32 (23): 2933–44.

  15. Rossini R., Musumeci G., Capodanno D. et al. Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of multicentre
    registry. Thromb Haemost. 2015; 113 (2): 272–82.

  16. Aradi D., Kirtane A., Bonello L. et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of
    platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J. 2015; 36 (27): 1762–71.

  17. Jin L., YuH., Dong T. et al. The prognostic value of ADP-induced
    platelet aggregation for bleeding complications in low — intermediate risk patients with acute coronary syndrome taking clopidogrel after percutaneous coronary intervention. Heart Lung Circulation. 2017; 26 (1): 49–57.

  18. Mehran R., Baber U., Steg G. et al. Cessation of dual antiplatelet
    treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational
    study. Lancet. 2013; 382 (9906): 1714–22.

  19. Cruden N., Din J., Janssen C. et al. Delay in filling first clopidogrel
    prescription after coronary stenting is associated with an increased
    risk of death and myocardial infarction. JAHA. 2014; 3 (3): e000669.

  20. Schoos M., Chandrasekhar J., Baber U. et al. Causes, timing and
    impact of dual antiplatelet therapy interruption for surgery (from
    the patterns of non-adherense to anti-platelet regimens in stented
    patients registry). Am J Cardiol. 2017 [Epub ahead of print]. DOI:
    10.1016/j.amjcard.2017.06.016.

  21. Kristensen S., Knuuti J., Saraste A. et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management. Eur Heart J. 2014; 35 (35): 2383–431.

  22. Agewall S., Cattaneo M., Collet J. et al. On behalf of ESC Working
    Group on Cardiovascular Pharmacology and Drug Therapy and ESC
    Working Group on Thrombosis. Eur Heart J. 2013; 34 (23): 1708–13.

  23. Sousa-Uva M., Storey R., Huber K. et al. On behalf of ESC Working Group on Cardiovascular Surgery and ESC Working Group on
    Thrombosis. Expert position paper on management of antiplatelet
    therapy in patients undergoing coronary artery bypass graft surgery. Eur Heart J. 2014; 35 (23): 1510–4.

  24. Price M., Walder J., Baker B. et al. Recovery of platelet function
    after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease. The
    Recovery Trial. JACC. 2012; 59 (25): 2338–43.

  25. Halvorsen S., Storey R., Rocca B. et al. Management of antithrombotic therapy aft er bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. Eur
    Heart J. 2017; 38 (19): 1455–62.

  26. Vassalotti J., Centor R., Turner B. et al. Practical approach to detection and management of chronic kidney disease for the primary
    care clinician. Am J Med. 2016; 129 (2): 153–62. e7. DOI: 10.1016/j.
    amjmed.2015.08.025.

  27. Carrero J., Varenhorst C., Jensevik K. et al. Long-term versus shortterm dual antiplatelet therapy was similarly associated with a lower
    risk of death, stroke, or infarction in patients with acute coronary
    syndrome regardless of underlying kidney disease. Kidney Int.
    2017; 91 (1): 216–26.

  28. Wiwiott S., Antman E., Winters K. et al. Randomized comparison
    of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12
    antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO) TIMI 26 Trial. Circulation. 2005; 111
    (25): 3366–73.

  29. Wiwiott D., Trenk D., Frelinger L. et al. PRINCIPLE-TIMI 44 Investigators. Circulation. 2007; 118 (25): 2923–32.

  30. Wiwiott S., Braunwald E., McCabe C. et al. TRITON-TIMI 38
    Investigators. Prasugrel versus clopidogrel in patients with acute
    coronary syndromes. N Engl J Med. 2007; 357 (20): 2001–15.

  31. Cannon C., Husted S., Harrington R. et al. For the DISPERSE-2
    Investigators. Safety, tolerability, and initial efficacy of AZD6140,
    the first reversible oral adenosine receptor antagonist, compared
    with clopidogrel, patients with non ST-segment elevation acute
    coronary syndrome. Primary results of the DISPERSE-2 Trial.
    JACC. 2007; 50 (19): 1844–50.

  32. Storey R., Becker R., Harrington R. et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J.
    2011; 32 (23): 2945–53.

  33. Campbell K., Cohn J., Fischman D. et al. Management of clopidogrel hypersensitivity without drug interruption. Am J Cardiol. 2011; 107 (6): 812–6.

  34. Koln P., Windecker S., Alfonso F. et al. ESC/EACTS Guidelines
    on myocardial revascularization. Eur Heart J. 2014; 35: 2541–619.

  35. O’Gara P., Kushner F., Ascheim D. et al. FССА/AHA Guideline for
    the management of ST-elevation myocardial infarction. A report
    of the American College of Cardiology Foundation/American
    Heart Association Task Force on practice guidelines. JACC. 2013;
    61 (4): 78–140.

  36. Levine G., Bates E., Bittl J. et al. 2016 ACC/AHA Guideline focused
    update on duration of dual antiplatelet therapy in patients with coronary artery disease. Circulation. 2016; 134 (10): e123–55.

  37. Cuisset T., Deharo P., Quilici J. et al. Benefit of switching dual antiplatelet therapy aft er acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J. 2017 [Epub ahead of print]. DOI: 10.1093/
    eurheartj/ehx175.

  38. Aradi D., Komosci A., Price M. et al. On behalf of tailored antiplatelet treatment study collaboration. Efficacy and safety of intensified
    antiplatelet therapy on basis of platelet reactivity testing in patients
    after percutaneous coronary interventions: systematic review and
    meta-analysis. Int J Cardiol. 2013; 167 (5): 2140–8.

Ключевые слова

агрегация тромбоцитов, клопидогрел, тикагрелор, прасугрел

Опубликована
2017-11-06
Как цитировать
БУРЯЧКОВСКАЯ, Людмила Ивановна et al. Значение особенностей действия антиагрегантов для выбора терапии сосудистого больного. Тромбоз, гемостаз и реология <br/><small>научно-практический журнал <br/>ISSN 2078–1008 (Print)</small>, [S.l.], n. 72, p. 6-13, nov. 2017. ISSN 2078-1008. Доступно на: <http://www.thrj.ru/index.php/thrj/article/view/69>. Дата доступа: 17 dec. 2017 doi: https://doi.org/10.25555/THR.2017.4.0803.